Comparative Pharmacology
Head-to-head clinical analysis: AEROLATE JR versus THEO DUR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AEROLATE JR versus THEO DUR.
AEROLATE JR vs THEO-DUR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Theophylline is a xanthine derivative that acts as a bronchodilator by relaxing bronchial smooth muscle. Its mechanism may involve inhibition of phosphodiesterase, increasing cyclic AMP, and adenosine receptor antagonism.
Inhibits phosphodiesterase, increasing cAMP levels; antagonizes adenosine receptors; enhances contractility of skeletal and cardiac muscle, and relaxes bronchial smooth muscle.
1-2 inhalations (35-50 mcg/inhalation) twice daily via oral inhalation.
300-600 mg orally twice daily
None Documented
None Documented
Terminal elimination half-life: 3.5-4.5 hours. This short half-life supports twice-daily dosing in asthma management, with trough levels remaining above therapeutic threshold.
Terminal elimination half-life: 3-9 hours in adults (smokers: 4-5 hours; nonsmokers: 6-9 hours); 20-30 hours in premature neonates; 1-5 hours in children. Prolonged in hepatic cirrhosis, heart failure, and with CYP1A2 inhibitors.
Renal elimination: 60-70% as unchanged drug and metabolites. Biliary/fecal excretion: 20-30%.
Primarily hepatic metabolism by CYP1A2 and CYP3A4; renal excretion of unchanged drug accounts for approximately 10% in adults, up to 50% in neonates; biliary/fecal excretion negligible.
Category C
Category C
Bronchodilator
Bronchodilator